Black Diamond Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Black Diamond Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to 2023.
  • Black Diamond Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.99M, a 27.6% decline year-over-year.
  • Black Diamond Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $10.5M, a 4.07% decline year-over-year.
  • Black Diamond Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $9.6M, a 21.3% decline from 2022.
  • Black Diamond Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $12.2M, a 13.1% decline from 2021.
  • Black Diamond Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $14M, a 80.8% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $9.6M -$2.59M -21.3% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-12
2022 $12.2M -$1.84M -13.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-12
2021 $14M +$6.27M +80.8% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 $7.77M +$4.12M +113% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 $3.64M +$3.58M +5683% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
2018 $63K Jan 1, 2018 Dec 31, 2018 10-K 2020-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.